Ultragenyx Pharmaceutical Inc. Files 8-K
Ticker: RARE · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations-update
Related Tickers: UGNX
TL;DR
UGNX filed an 8-K on Jan 12, 2025, standard financial update.
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing does not contain specific financial figures or operational details in the provided text, but indicates a standard reporting event.
Why It Matters
This filing signals a routine update on Ultragenyx's financial status and operational results, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for reporting financial and operational results, with no immediate negative or positive news indicated in the provided text.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Filing date
- 60 Leveroni Court, Novato, California 94949 (address) — Principal Executive Offices
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing does not contain specific financial figures or operational details, only indicating that the report pertains to 'Results of Operations and Financial Condition'.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing is January 12, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on January 13, 2025.
What is the principal executive office address for Ultragenyx Pharmaceutical Inc.?
The principal executive office address for Ultragenyx Pharmaceutical Inc. is 60 Leveroni Court, Novato, California 94949.
What is the Commission File Number for Ultragenyx Pharmaceutical Inc.?
The Commission File Number for Ultragenyx Pharmaceutical Inc. is 001-36276.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-01-13 08:30:33
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
Filing Documents
- rare-20250112.htm (8-K) — 44KB
- rare-ex99_1.htm (EX-99.1) — 41KB
- img45776771_0.jpg (GRAPHIC) — 19KB
- 0000950170-25-004587.txt ( ) — 229KB
- rare-20250112.xsd (EX-101.SCH) — 23KB
- rare-20250112_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, Ultragenyx Pharmaceutical Inc. (the " Company ") issued a press release (the " Press Release ") announcing preliminary unaudited fiscal year 2024 total revenue results, revenue for Crysvita and revenue for Dojolvi, cash, cash equivalents and available-for-sale investments at 2024 fiscal year end and financial guidance for 2025. The Company expects to report its full year results for the 2024 fiscal year in February 2025. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 12, 2025 104 The cover page from the Company's Current Report on Form 8-K dated January 12, 2025 formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: January 13, 2025 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy